Efficacy and Safety of Topical Unpreserved 0.1% Fluorometholone Ophthalmic Solution on Dry Eye Syndrome.
10.3341/jkos.2013.54.2.215
- Author:
Joon Ho PARK
1
;
Jun Hun LEE
;
Young Jeung PARK
;
Hong Kyun KIM
Author Information
1. Department of Ophthalmology, Kyungpook National University School of Medicine, Daegu, Korea. okeye@knu.ac.kr
- Publication Type:Clinical Trial ; Original Article ; Randomized Controlled Trial
- Keywords:
Dry eye syndrome;
Tear film parameters;
Topical unpreserved 0.1% fluorometholone
- MeSH:
Dry Eye Syndromes;
Eye;
Fluorometholone;
Humans;
Intraocular Pressure;
Methylprednisolone;
Osmolar Concentration;
Tears
- From:Journal of the Korean Ophthalmological Society
2013;54(2):215-223
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To evaluate the efficacy and safety of topical unpreserved 0.1% fluorometholone (FML) ophthalmic solution in patients with dry eye syndrome. METHODS: Patients with mild to moderate dry eye syndrome were divided into the control group (Group I), topical unpreserved 0.1% FML group (Group II), and topical preserved 0.1% FML group (Group III). Intraocular pressure (IOP), Ocular Surface Disease Index (OSDI), tear film break-up time (TF-BUT), Oxford stain score (OSS), and tear osmolarity (Tosm) were evaluated at 2 weeks, 4 weeks, 8 weeks, and 12 weeks (Trial 1). Patients with severe dry eye syndrome were divided into 1% methylprednisolone (MP) group (Group I) and 0.1% unpreserved FML group (Group II). Same parameters were evaluated in both groups (Trial 2). RESULTS: In clinical trial I, OSS scores of Group II were lower than other groups (p < 0.05). For severe dry eye patients in clinical trial 2, there were no significant differences in all parameters between the 2 groups. CONCLUSIONS: Topical unpreserved 0.1% fluorometholone was shown to be an effective and relatively safe treatment in patients with dry eye syndrome.